What does PARP use NAD+ for?

As the building block for poly(ADP-ribose) chains, which recruit repair machinery to DNA damage.

Can it deplete the pool?

Yes. Sustained or extensive damage means continuous consumption, which under severe conditions can compromise other NAD-dependent processes.

Does a low NAD+ level mean less is being made?

Not necessarily. It can mean reduced synthesis or increased consumption, and the level alone does not distinguish them.

NAD+

DNA Damage Draws Down the Pool

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Poly(ADP-ribose) polymerases respond to DNA damage by building ADP-ribose polymers, using NAD+ as the building block. Extensive or sustained damage can therefore consume a substantial fraction of the cellular pool.

Key facts

Family: Poly(ADP-ribose) polymerases (PARPs)
Trigger: DNA damage, particularly strand breaks
Substrate: NAD+, used as ADP-ribose donor
Product: Poly(ADP-ribose) chains
Consequence: Pool depletion under heavy damage
Review: Thapa 2021 (PMID 33387580)

What PARP does when DNA breaks

It binds the break and begins building branched chains of ADP-ribose on itself and on nearby proteins. Those chains are a recruitment signal — highly charged, immediately visible to repair machinery, and rapidly assembled. It is among the fastest responses a cell mounts to genomic damage.

Where the building material comes from

NAD+. Each ADP-ribose unit added to a chain is taken from an NAD+ molecule, releasing nicotinamide. That makes NAD+ a raw material here rather than a cofactor, and the chains can be long, so the consumption per damage event is not trivial.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

Why this can deplete the pool

Sustained or extensive DNA damage means sustained PARP activity, and sustained PARP activity means continuous NAD+ consumption. Under severe damage the draw can be large enough to compromise processes elsewhere that also need NAD+, including energy metabolism — so a repair response can create a metabolic problem.

The connection to the other consuming enzymes

Sirtuins consume NAD+ as a co-substrate. CD38 cleaves it extracellularly. PARPs use it as a polymer building block. Three families with unrelated functions all drawing on one pool means competition between them, and it is why NAD+ concentration is a shared resource rather than a private one.

Why PARP is a drug target

Thapa and colleagues reviewed PARP-1 as a target for neurodegenerative disease in Life Sciences in 2021, and PARP inhibitors are established in oncology on a separate rationale. An enzyme sitting at the junction of DNA repair and energy metabolism has several routes to therapeutic interest, which is why it appears in unrelated fields.

What this establishes about NAD+ levels

That they reflect demand as well as supply. A fall in NAD+ can mean less is being made or more is being consumed, and those have different causes and different implications. Measuring the level alone does not distinguish them — which is worth remembering when a decline is reported.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What does PARP use NAD+ for?: As the building block for poly(ADP-ribose) chains, which recruit repair machinery to DNA damage.
Can it deplete the pool?: Yes. Sustained or extensive damage means continuous consumption, which under severe conditions can compromise other NAD-dependent processes.
Does a low NAD+ level mean less is being made?: Not necessarily. It can mean reduced synthesis or increased consumption, and the level alone does not distinguish them.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum